Morton Alexander P, Moore Ernest E, Moore Hunter B, Gonzalez Eduardo, Chapman Michael P, Peltz Erik, Banerjee Anirban, Silliman Christopher
Department of Surgery-Trauma Research Center, University of Colorado, Denver, Colorado.
Department of Surgery-Trauma Research Center, University of Colorado, Denver, Colorado; Department of Surgery-Denver Health Medical Center, Denver, Colorado.
J Surg Res. 2017 Jun 1;213:166-170. doi: 10.1016/j.jss.2015.04.077. Epub 2015 Apr 25.
Hyperfibrinolysis plays an integral role in the genesis of trauma-induced coagulopathy. Recent data demonstrate that red blood cell lysis promotes fibrinolysis; however, the mechanism is unclear. Hemoglobin-based oxygen carriers (HBOCs) have been developed for resuscitation and have been associated with coagulopathy. We hypothesize that replacement of whole blood (WB) using an HBOC results in a coagulopathy because of the presence of free hemoglobin.
WB was sampled from healthy donors (n = 6). The clotting profile of each citrated sample was evaluated using native thromboelastography. Serial titrations were performed using both HBOC (PolyHeme) and normal saline (NS; 5%, 25%, and 50%) and evaluated both with and without a 75-ng/mL tissue plasminogen activator (tPA) challenge. Tranexamic acid (TXA) was added to inhibit plasmin-dependent fibrinolysis. Fibrinolysis was measured and recorded as lysis at 30 min (LY30), the percentage of clot LY30 after maximal clot strength. Dilution of WB with NS or HBOC was correlated using LY30 via Spearman rho coefficients. Groups were also compared using a Friedman test and post hoc analysis with a Bonferroni adjustment.
tPA-provoked fibrinolysis was enhanced by both HBOC (median LY30 at 5%, 25%, and 50% titrations: 11%, 21%, and 44%, respectively; Spearman = 0.94; P < 0.001) and NS (11%, 28%, and 58%, respectively; Spearman = 0.790; P < 0.001). However, HBOC also enhanced fibrinolysis without the addition of tPA (1%, 4%, 5%; Spearman = 0.735; P = 0.001) and NS did not (1%, 2%, 1%; r = 0.300; P = 0.186. Moreover, addition of TXA did not alter or inhibit this fibrinolysis (WB versus 50% HBOC: 1.8% versus 5.7%, P = 0.04). There was no significant difference in fibrinolysis of HBOC with or without TXA (50% HBOC versus 50% HBOC + TXA: 5.6% versus 5.7%, P = 0.92). In addition, the increased fibrinolysis seen with NS was reversed when TXA was present (WB versus 50% NS: 1.8% versus 1.7%, P = 1.0).
HBOCs enhance fibrinolysis both with and without addition of tPA; moreover, this mechanism is independent of plasmin as the phenomenon persists in the presence of TXA. Our findings indicate the hemoglobin molecule or its components stimulate fibrinolysis by both tPA-dependent and innate mechanisms.
高纤溶在创伤性凝血病的发生过程中起着不可或缺的作用。最近的数据表明,红细胞溶解会促进纤溶;然而,其机制尚不清楚。基于血红蛋白的氧载体(HBOCs)已被开发用于复苏,且与凝血病有关。我们假设,使用HBOC替代全血(WB)会因游离血红蛋白的存在而导致凝血病。
从健康供体(n = 6)采集WB。使用天然血栓弹力图评估每个枸橼酸盐样本的凝血情况。使用HBOC(聚血红素)和生理盐水(NS;5%、25%和50%)进行系列滴定,并在有和没有75 ng/mL组织纤溶酶原激活剂(tPA)激发的情况下进行评估。加入氨甲环酸(TXA)以抑制纤溶酶依赖性纤溶。测量纤溶并记录为30分钟时的溶解(LY30),即最大凝块强度后凝块LY30的百分比。通过Spearman相关系数使用LY30将NS或HBOC对WB的稀释进行相关性分析。还使用Friedman检验和经Bonferroni校正的事后分析对组间进行比较。
tPA诱发的纤溶在HBOC(5%、25%和50%滴定的中位LY30分别为:11%、21%和44%;Spearman = 0.94;P < 0.001)和NS(分别为11%、28%和58%;Spearman = 0.790;P < 0.001)作用下均增强。然而,HBOC在未添加tPA时也增强了纤溶(1%、4%、5%;Spearman = 0.735;P = 0.001),而NS则没有(1%、2%、1%;r = 0.300;P = 0.186)。此外,加入TXA并未改变或抑制这种纤溶(WB与50% HBOC相比:1.8%对5.7%,P = 0.04)。添加或不添加TXA时HBOC的纤溶无显著差异(50% HBOC与50% HBOC + TXA相比:5.6%对5.7%,P = 0.92)。此外,当存在TXA时,NS导致的纤溶增加得以逆转(WB与50% NS相比:1.8%对1.7%,P = 1.0)。
无论是否添加tPA,HBOC均会增强纤溶;此外,该机制独立于纤溶酶,因为在存在TXA的情况下该现象仍然存在。我们的研究结果表明,血红蛋白分子或其成分通过tPA依赖性和固有机制刺激纤溶。